The purpose of this phase II trial was to assess the efficacy and toxicity of paclitaxel and nedaplatin (TN) as the initial postoperative adjuvant chemotherapy for uterine cervical cancer with lymph node metastases (LNM). Patients with FIGO stage IB1-IIA2 squamous cell carcinoma of the uterine cervix were enrolled. Histological confirmation of LNM was mandatory. Intravenous paclitaxel at 175 mg/m 2 and nedaplatin at 80 mg/m 2 were administered every 28-day cycle, of which there were 5 cycles after radical hysterectomy. Sixty-two patients were enrolled in the study from November 2011 to July 2015. Their median age was 48.5 years (range 28-64).
patients with prognostic risk factors for recurrence receive postoperative adjuvant therapy. Peters et al. 3 showed a significant survival advantage associated with the use of CCRT rather than RT alone in patients with high-risk cervical cancer. In the guidelines for cervical cancer of several countries, the pathological findings of lymph node metastasis (LNM) and/or parametrial invasion (PMI) are defined as high-risk prognostic factors, and postoperative CCRT is recommended as adjuvant treatment for these cases. [4] [5] [6] [7] [8] There has recently been much debate regarding the risk-benefit balance of postoperative CCRT for cervical cancer. [9] [10] [11] [12] Patients with LNM have been shown to exhibit a greater rate of distant failure than those without this, 9,10 so postoperative adjuvant therapy should not only control local recurrence, but also prevent distant metastasis.
Postoperative CCRT would be expected to induce serious toxicities, which could continue throughout the patient's life; this is because the organ in the pelvis targeted by RT has already been subjected to radical surgery. 11, 12 In this context, systemic chemotherapy (CT) alone could play an important role as postoperative adjuvant therapy for patients with high-risk cervical cancer.
The combination of paclitaxel plus platinum is standard treatment for patients with advanced/recurrent cervical cancer. 13, 14 Nedaplatin (cis-diammine glycolato platinum) was developed as a less nephrotoxic and neurotoxic analog of cisplatin. We showed that the combination of paclitaxel plus nedaplatin (TN) would have favorable antitumor activity and be feasible for advanced/recurrent cervical cancer. 15 Recently, Li et al. 16 showed the efficacy of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced/ recurrent cervical cancer.
We conducted a phase II trial involving the application of postoperative systemic CT alone with the combination of paclitaxel plus nedaplatin to uterine cervical cancer patients with LNM, to evaluate the efficacy and toxicity of this regimen.
| MATERIALS AND METHODS
All patients provided written informed consent before enrollment.
The trial was registered with the UMIN-Clinical Trials Registry 
| Eligibility
Patients who had undergone radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB1, IB2 or IIA of uterine cervix were enrolled in this trial. Histological type included squamous cell carcinoma alone. Histological confirmation of LNM was mandatory.
In addition, patients had to have: no residual tumor after surgery; age ranging from 20 to 70; and ECOG performance status score 0-1. Patients were also required to have adequate hematological (absolute neutrophil count [ANC] ≥1500/lL, platelets ≥100 000/ lL, hemoglobin ≥9.0 g/dL), renal (creatinine ≤1.5 mg/dL) and hepatic function (bilirubin ≤1.2 mg/dL, sGOT/GPT ≤100 U/L). Patients were excluded from the study if they had para-aortic LNM confirmed histologically, a positive surgical margin or peritoneal metastasis. 
| Treatment

| Follow-up evaluation
Prior to each cycle of treatment, a physical examination, routine hematologic studies and blood chemistry analysis were conducted.
Once protocol treatment had ended, the patients were evaluated by pelvic examination, Papanicolaou tests, and an analysis of serum squamous cell carcinoma antigen level at the discretion of the attending physician every 1-3 months in the first 2 years, and every 4-6 months during years 3, 4 and 5. In addition, patients underwent a CT or MRI scan every 6 months in the first 2 years and annually thereafter until 5 years.
| Statistical methods
The sample size was initially calculated based on the assumption of an expected 2-year relapse-free survival (RFS) rate of 80% and the threshold value of 65%, which was based on previously published data. [15] [16] [17] [18] Under these assumptions, 58 patients were required to achieve a 1-sided significance level of 5% with power of 85%. Factoring in a 5% dropout rate, we set a target sample size of 63 patients. The primary endpoint of the current study was 2-year RFS, defined as the interval between the date of entry into the study and the date of the first physical or radiographic evidence of disease recurrence. The secondary endpoints were overall survival (OS), adverse events and rate of completion of protocol treatment. OS was calculated from the date of entry into the study to the date of death or last follow-up visit. RFS and OS were calculated using the Kaplan-Meier method, and their confidence intervals (CI) were estimated by Greenwood's formula.
All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).
3 | RESULTS
| Patient characteristics
Sixty-two patients were enrolled from 14 institutions between November 2011 and July 2015. All patients were eligible for this study, so data from 62 patients were included in the analysis. The baseline characteristics of the patients are shown in Table 1 
| Adverse events
The adverse events are summarized in Table 2 . Thirty-seven patients (60.7%) had grade 3-4 neutropenia, while 1 (1.6%) had grade 3-4
anemia. Febrile neutropenia occurred in 1 patient alone (1.6%).
There was no severe thrombocytopenia. With regard to non-hematological toxicities, the most common adverse event was alopecia (all grades, 95.0%). Sensory neuropathy (all grades, 81.7%), myalgia/ arthralgia (all grades, 66.7%) and fatigue (all grades, 55.7%) were also common, but there were no grade 3-4 non-hematological adverse events in 5% or more of the patients.
Whether the number of dissected lymph nodes was associated with toxicity in all grades was evaluated. Neutropenia was more common in patients with ≥40 dissected lymph nodes than in those with <40 (87.5% vs 65.5%, P = .041); in contrast, thrombocytopenia was rarer in patients with 40 or more dissected lymph nodes than in those with <40 (0% vs 13.8%, P = .030). The other toxicities had no significant difference between the 2 groups.
| Survival analysis
The median follow-up duration was 45.7 months (range 23.4-69.5).
Follow-up data from all patients were available. Data regarding recurrence and death are shown in Table 3 . Among 15 patients with recurrence, 9 patients had locoregional recurrence, 5 had distant recurrence, and 1 had both. All 7 deaths were caused by deterioration of the disease. Figure 1A ,B).
| DISCUSSION
We report the positive results of a phase II trial involving the application of postoperative systemic CT alone to uterine cervical cancer patients with lymph node metastases. Adjuvant CT alone with TN after radical hysterectomy was demonstrated to be an effective and feasible treatment.
In the current phase II study, the 2-year RFS, 2-year OS and estimated 4-year OS rates were 79.0%, 93.5% and 87.1%, respectively, which were comparable to those seen in previous reports of adjuvant CCRT for the patients with high-risk factors; 3, 17, 18 nevertheless, the patients in the current study would have more severe risk factors than those in most previous studies. All patients in the current study had LNM, among which approximately 30% had 2-3 metastases, approximately 20% had 5 or more metastases, and approximately 20% had common iliac lymph node metastases. Peters et al. 3 showed that the estimated 4-year PFS and OS rates for patients receiving CCRT were 80% and 81% in a phase III trial in which approximately 90% of patients had nodal involvement and 3% had common iliac nodal involvement. Sehouli et al. 17 showed that the 2-year PFS was 81.8% and the estimated 5-year OS was 77.4% for patients receiving CCRT. In the study by Sehouli et al., only half of the patients had nodal involvement.
Adjuvant chemotherapy alone with TN after radical hysterectomy was demonstrated to be safe and feasible. In the current study, 90.3% of patients completed the treatment protocol as planned and grade 3-4 gastrointestinal toxicities occurred in only 1 patient. There has recently been much debate regarding the risk-benefit balance of postoperative CCRT for cervical cancer. [9] [10] [11] [12] Postoperative CCRT would be expected to induce serious gastrointestinal toxicity, which could continue throughout the patient's life; this is because the organ in the pelvis that would be targeted by RT has already been subjected to radical surgery. 11, 12 Takekuma et al. 11, 12 report that the level of invasiveness of the surgical procedure might be associated with the toxicities of adjuvant CCRT, which meant that patients with ≥40 dissected lymph nodes had significantly more non-hematological toxicities of adjuvant CCRT than those with <40. They suggested that, for patients undergoing CCRT, the use of this radical surgery to increase the possibility of a permanent cure has to be balanced against the possibility of developing a serious illness in association with the postoperative therapy. In this context, systemic CT alone could play an important role as postoperative adjuvant therapy for patients with high-risk cervical cancer. 12 In the current study, the rates of severe non-hematological toxicity were only 0%-6.6%
( Table 2 ). The evaluation of whether the number of dissected lymph nodes was associated with toxicity in all grades showed that there were significant differences regarding neutropenia and thrombocytopenia between patients with ≥40 dissected lymph nodes and those with <40, the reason for which was unclear. However, non-hematological toxicities did not differ significantly between the 2 groups.
These findings suggest that postoperative TN therapy could be undergone safely regardless of the level of invasiveness of the surgical procedure.
In the current study, no severe neurotoxicity or thrombocytopenia occurred, which matched the results of a previous phase II study revealing the efficacy of TN therapy for advanced/recurrent cervical cancer. 15 Currently, paclitaxel combined with carboplatin (TC) is 
18-21
Matsuo et al. 22 showed in a multi-institutional retrospective study that systemic chemotherapy might be as effective a postoperative treatment as radiation-based therapy in node-positive stage IB-IIB cervical cancer. In a phase III trial conducted by Curtin et al.,
patients were randomized to systemic CT alone and systemic CT followed by whole pelvic RT after radical hysterectomy. Although this trial could not achieve a positive result regarding the primary endpoint, they conclude that the patterns of recurrence were statistically similar between the 2 arms, and both regimens were well tolerated. 23 The current study has a few limitations. First, the follow-up period was short. The expected survival duration of the patients in the current study would be relatively long because this is a study on early-stage disease. A secondary endpoint in the current study is the 5-year OS, for which the results will be reported at a later date. Second, the late adverse events could not be reported. The standard postoperative adjuvant therapy is RT or CCRT in which severe late adverse events have occurred, and so compared with this standard treatment, data of the late adverse event of CT alone would be important. Third, in the current study, no restrictions were placed on the surgical procedure performed; namely, radical hysterectomy or lymphadenectomy. The results of postoperative adjuvant therapy could be affected by the outcome of the surgery performed before the study.
In summary, adjuvant CT alone with TN after radical hysterectomy for patients with high-risk early-stage cervical cancer was demonstrated to be an effective and feasible treatment. We suggest that a prospective randomized study be conducted with the aim of testing the noninferiority of systemic CT alone to CCRT as optimal adjuvant therapy for patients with factors placing them at high risk for recurrence.
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